Behavioural and Psychological Symptoms of Dementia (BPSD): Effects of EGb 761®

R. Hoerr

doi:10.1055/s-2003-40451

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2003; 36: 56-61
DOI: 10.1055/s-2003-40451

Original Paper

Behavioural and Psychological Symptoms of Dementia (BPSD): Effects of EGb 761®

R. Hoerr¹

¹Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany

Abstract

Dementia patients often present with behavioural and psychological symptoms, with prevalence rates reaching 90 %. It is therefore important to know whether an antidementia drug that improves cognitive function can also reduce the burden of behavioural and psychological symptoms of dementia, and whether it can improve cognitive function in patients suffering from such non-cognitive symptoms. Therefore, three types of study with Ginkgo special extract EGb 761® (definition see editorial) were reviewed: 1) studies on patients with impairment of cerebral function or dementia associated with behavioural and psychological symptoms (BPSD); 2) studies on patients suffering from impairment of cerebral function and depression; 3) dementia studies on patient samples with a high prevalence of BPSD. Compared to placebo, EGb 761® improved these symptoms significantly in all studies that used a scale to measure the presence and intensity of BPSD. Moreover, EGb 761® was found to be superior to placebo with respect to improvement in cognitive function, daily living activities and global assessment in dementia patients suffering from BPSD. It may be concluded that EGb 761® is of particular interest to patients with dementia and BPSD since it improves both the patient’s cognitive ability and behavioural and psychological symptoms.

Key words

Ginkgo - EGb 761® - Dementia - BPSD - Depression - HAMD - SCAG

Full Text

References

1 Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt. 1906; 23 1129-1136
2 American Psychiatric A ssociation. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. DSM-IV. Washington, DC; American Psychiatric Association 1999
3 Blessed G, Tomlinson B E, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit J Psychiat. 1968; 114 797-811
4 Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J. et al . The effects of donepezil in Alzheimer’s disease - Results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10 237-244
5 Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study G roup. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. International Journal of Geriatric Psychopharmacology. 1998; 1 55-65
6 Drevets W C, Rubin E H. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989; 25 39-48
7 Düker H, Lienert G A. KLT-Konzentrations-Leistungs-Test. Handanweisung. Göttingen; Hogrefe 1965
8 Erzigkeit H. Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeits- und Gedächtnisstörungen. Vaterstetten; Vless 1986
9 Finkel S I, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of demenia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8 (Suppl 3) 497-500
10 Finkel S I. Module 1. An introduction to BPSD. In Finkel SI, editor. Behavioral and psychological symptoms of dementia. Educational Pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-19
11 Folstein M F, Folstein S E, McHugh P R. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975; 12 189-198
12 Förstl H. Neuropathology of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2000; 12 (Suppl 1) 77-81
13 Guy W (ed.). ECDEU Assessment Manual for Psychopharmacology. Rockville, Md; US Dept. of Health, Education and Welfare, National Institute of Mental Health 1976: p. 218-222
14 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23 56-62
15 Hofferberth B. The efficacy of EGb 761® in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology. 1994; 9 215-222
16 Hope T, Keene J, Fairburn C G, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study. Br J Psychiatry. 1999; 174 39-44
17 Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T. et al . Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia. J Neurol Sci. 1997; 153 76-81
18 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hoerr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiat. 1996; 29 47-56
19 Knapp M J, Knopman D S, Solomon P R, Pendlebury W W, Davis C S, Gracon S I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA. 1994; 271 985-991
20 Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg AF for the North American EGb Study G roup. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997; 278 1327-1332
21 Lebowitz B D. Behavioral and psychological symptoms of dementia: A clinical and research update. Int Psychogeriatr. 2000; 12 (Suppl 1) 19-21
22 Levy M L, Cummings J L, Fairbanks L A, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry. 1996; 153 1438-1443
23 Luxenberg J. Module 2. Clinical issues. In Finkel SI, editor Behavioral and psychological symptoms of dementia. Educational pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-29
24 Lyketsos C G, Steinberg M, Tschanz J T, Norton M C, Steffens D C, Breitner J CS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry. 2000; 157 708-714
25 Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (EGb) compared to placebo in the treatment of patients affected by senile psychorganic dementia on an arteriosclerotic basis. Gazz Med Ital - Arch Sci Med. 1993; 152 69-80
26 Mega M S, Cummings J L, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996; 46 130-135
27 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat. 1979; 134 382-389
28 Münch G, Schinzel R, Loske C, Wong A, Durany N, Li J J. et al . Alzheimer’s disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 1998; 105 439-446
29 Oswald W D, Fleischmann U M. Nuremberg Gerontopsychological Inventory (NAI). Göttingen; Hogrefe 1995
30 Porsolt R D, Martin P, Fromage S, Lenègre A, Drieu K. Anti-stress effects of EGb 761® in rodent models. In Cristen Y, Costentin J, Lacour M, editors Effects of Ginkgo biloba extract (EGb 761) on the central nervous system. Paris; Elsevier 1992: p. 135-145
31 Prilipko L. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In Packer L, Prilipko L, Christen Y, editors Free radicals in the brain. Berlin; Springer 1992: p. 146-152
32 Ramassamy C, Christen Y, Clostre F, Costentin J. The Ginkgo biloba extract, EGb 761®, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol. 1992; 44 943-945
33 Rapin J R, Lamproglou I, Drieu K, DeFeudis F V. Demonstration of the ”anti-stress” activity of an extract of Ginkgo biloba (EGb 761®) using a discrimination learning task. Gen Pharmac. 1994; 25 1009-1016
34 Reisberg B, Borenstein J, Salob S P, Ferris S H. Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48 (Suppl) 9-15
35 Reisberg B, Ferris S H, de Leon M J, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139 1136-1139
36 Rogers S I, Farlow M R, Doody R S, Mohs R, Friedhoff LT and the Donepezil Study G roup. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998; 50 136-145
37 Rosen W G, Mohs R C, Davis K L. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984; 141 1356-1364
38 Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H B,. et al . Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Brit Med J. 1999; 318 633-640
39 Sattel H, Geiger-Kabisch C, Schreiter-Gasser U, Besthorn C, Förstl H. Häufigkeit und Bedeutung ”nicht-kognitiver” Symptome bei der Demenz vom Alzheimer-Typ: produktiv psychotische Symptomatik, depressive Störungen und Störungen des Verhaltens. Z Gerontol. 1993; 26 275-279
40 Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of Ginkgo biloba extract EGb 761® in combination with antidepressants. Geriatrie Forschung. 1993; 3 45-53
41 Schwartz G E. Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI). Psychol Rep. 1983; 53 479-488
42 Shader R I, Harmatz J S, Salzman C. A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment Geriatric (SCAG). J Am Geriat Soc. 1974; 22 107-113
43 Stocksmeier U, Eberlein M. Depressive Verstimmung bei Hirnleistungsstörungen. Wirkung eines Ginkgo-biloba-Extraktes in Doppelblind-Studie überprüft. TW Neurologie Psychiatrie. 1992; 6 74-76
44 Weidenhammer W, Fischer B. c. I.-Skala, ein Selbstbeurteilungsverfahren zur Objektivierung leichter cerebraler Insuffizienzen. Ebersberg; Vless-Test 1987
45 Weitbrecht W U, Jansen W. Ginkgo biloba extract in the treatment of primary degenerative dementia. Placebo-controlled, double-blind and comparative study. Fortschr Med. 1986; 104 199-202
46 Winter J C, Timineri D. The discriminative stimulus properties of EGb 761®, an extract of Ginkgo biloba. Pharmacol Biochem Behav. 1999; 62 543-547
47 Zhang X Y, Zhou D F, Su J M, Zhang P Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol. 2001; 21 85-88
48 Zhang X Y, Zhou D F, Zhang P Y, Wu G Y, Su J M, Cao L Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001; 62 878-883

Dr. med. Robert Hoerr

Leiter Geriatrie/ZNS

Dr. Willmar Schwabe GmbH & Co. KG

Willmar-Schwabe-Str. 4

76227 Karlsruhe

Germany